Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5956872 | PMC |
| http://dx.doi.org/10.4103/idoj.IDOJ_144_17 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Understanding the Intricate Pathophysiology of Psoriasis and Related Skin Disorders.
Int J Mol Sci
January 2025
Department of Dermatology, Faculty of Medicine, University of Medicine and Pharmacy of Craiova, 200349 Craiova, Romania.
Psoriasis is a chronic inflammatory condition that is polygenic and multisystemic, impacting approximately 2-3% of the global population. The onset of this disease is influenced by an intricate interplay of genetic and environmental factors, predisposing individuals to the psoriasis phenotype. The complex pathogenesis of psoriasis contains certain key aspects found in other autoinflammatory and autoimmune dermatological diseases.
View Article and Find Full Text PDFClinical features and prognosis of anti-MDA5-positive dermatomyositis with coexistent anti-aminoacyl-tRNA synthetase antibodies.
Clin Rheumatol
January 2025
Department of Rheumatology and Immunology, The Second Affiliated Hospital of Soochow University, Suzhou, Jiangsu, China.
Objectives: This study aimed to evaluate the incidence and clinical significance of coexistence of anti-aminoacyl-tRNA synthetase (anti-ARS) antibody in patients with anti-melanoma differentiation-associated gene 5-positive dermatomyositis (anti-MDA5 + DM).
Methods: We assessed a cohort of 246 consecutive patients with anti-MDA5 + DM. Clinical characteristics and survival rates were compared between patients with and without anti-ARS antibodies.
Idiopathic inflammatory myopathies related lung disease in adults.
Lancet Respir Med
November 2024
Department of Pulmonary and Critical Care Medicine, Integrated Hospital Care Institute, Cleveland Clinic, Cleveland, OH, USA.
Article Synopsis
- Interstitial lung disease (ILD) frequently occurs in adults with idiopathic inflammatory myopathies, particularly those with antisynthetase syndrome and anti-MDA5 antibodies, manifesting in various severities from mild to rapidly worsening symptoms.
- Common symptoms include lung issues along with myositis, skin lesions, arthritis, and Raynaud’s phenomenon, but 16-65% may have lung problems as the only indication.
- Treatment typically involves immunosuppression, combining therapies for aggressive cases, and possibly lung transplantation for severe cases, although short-term mortality is notably high in rapidly progressive disease associated with anti-MDA5 antibodies.
Autoantibodies against a subunit of mitochondrial respiratory chain complex I in inclusion body myositis.
J Autoimmun
December 2024
Karolinska Institutet, Division of Rheumatology, Department of Medicine, Solna, Stockholm, Sweden; Department of Gastroenterology, Dermatology and Rheumatology, Karolinska University Hospital, Stockholm, Sweden; Karolinska Institutet, Center for Molecular Medicine, Stockholm, Sweden.
Background: Autoantibodies are found in up to 80 % of patients with idiopathic inflammatory myopathies (IIM) and are associated with distinct clinical phenotypes. Autoantibodies targeting cytosolic 5'-nucleotidase 1A (anti-NT5C1A) are currently the only known serum biomarker for the subgroup inclusion body myositis (IBM), although detected even in other autoimmune diseases. The aim of the study was to identify new autoimmune targets in IIM.
View Article and Find Full Text PDFA Novel Treatment for Skin Manifestations in Dermatomyositis: A Case Report.
Cureus
August 2024
Rheumatology, Hackensack University Medical Center, Hackensack, USA.
We present a case of refractory cutaneous dermatomyositis (DM) in a 51-year-old Hispanic female which failed multiple treatments but found symptomatic relief with anifrolumab. Anifrolumab was the only treatment that was associated with significant improvement in the rash and pruritis of the patient and lowered her corticosteroid needs. To our knowledge, this is the only second case report that has shown success in treating refractory cutaneous symptoms of DM with anifrolumab after failing standard and multiple combinations of therapies.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!